(112 days)
Not Found
No
The document describes a PCR-based diagnostic test with automated data interpretation by the instrument's software, but there is no mention of AI or ML algorithms being used for this interpretation or any other part of the process.
No
This device is an in vitro diagnostic test designed to detect the presence of Group B streptococcus DNA. It provides diagnostic information rather than directly treating or preventing disease.
Yes
The "Intended Use" explicitly states that the IDI-Strep B™ assay is a "qualitative in vitro diagnostic test for the rapid detection of Group B streptococcus (GBS) DNA". Furthermore, the "Device Description" clarifies that it "can be used as the sole diagnostic information at the time of delivery for establishing GBS colonisation status". These statements directly indicate its purpose as a diagnostic tool.
No
The device description clearly outlines a physical in vitro diagnostic test involving sample preparation, PCR amplification, and detection using a dedicated hardware analyzer (Smart Cycler®). While software is used for data interpretation, the core of the device is a biological assay and associated hardware.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section explicitly states: "IDI-Strep B™ assay is a qualitative in vitro diagnostic test..."
- Purpose: The device is designed to detect Group B streptococcus (GBS) DNA in human specimens (vaginal/rectal swabs) to establish GBS colonization status. This is a diagnostic purpose performed outside of the body.
- Methodology: It utilizes laboratory techniques (PCR and fluorogenic hybridization) to analyze biological samples.
All of these points align with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
IDI-Strep B™ assay is a qualitative in vitro diagnostic test for the rapid detection of Group B streptococcus (GBS) DNA in vaginal/rectal specimens from prepartum or intrapartum women. The test performed on the Smart Cycler® automated analyzer utilizes polymerase chain reaction (PCR) for the amplification of a cfb gene sequence of GBS recovered from clinical samples and fluorogenic target-specific hybridization for the detection of the amplified DNA.
IDI-Strep B™ assay can be used to establish GBS colonisation status of prepartum and intrapartum women.
Product codes (comma separated list FDA assigned to the subject device)
NJR
Device Description
IDI-Strep B™ assay is a qualitative in vitro diagnostic test for the rapid detection of Group B streptococcus (GBS) in vaginal/rectal specimens from intrapartum maternity patients. The test performed on the Smart Cycler® automated analyzer utilizes polymerase chain reaction (PCR) for the amplification of GBS DNA recovered from clinical samples and fluorogenic target-specific hybridization for the detection of the amplified GBS DNA.
IDI-Strep B™ assay can be used as the sole diagnostic information at the time of delivery for establishing GBS colonisation status of intrapartum maternity patients.
Test Description: GBS collected from a vaginal/rectal swab is resuspended in sample preparation buffer. A sample is added to the lysing tube containing glass beads. The proprietary procedure is based on a combination of chemical and physical (glass beads) action and takes less than 10 minutes. A sample of the lysate solution is then added to the tube containing the PCR master mix which has the GBS-specific primers used to amplify the GBS ofb gene, if present, and the internal control (IC) template. Finally, 25 µi is transferred to the reaction tube which is placed in the Smart Cycler® assay.
Amplified target DNA is detected with hybridization probes labeled with quenched fluorophores, i.e. molecular beacons. Different fluorophores are used for the GBS amplicon and for the detection of the IC amplicon. Their detection is independent of one another. Amplification of the internal control monitors for inhibitors potentially introduced with the clinical specimen and, in negative specimens, confirms the integrity of assay reagents. The interpretation of the data collected by the Smart Cycler® is made entirely by the diagnostic software of the Smart Cycler® instrument.
The amount of fluorescence at any given cycle, or following cycling, depends on the amount of specific amplicon present at that time. The Smart Cvcler® instrument monitors simultaneously the fluorescence emitted by each beacon, interprets all data and at the end of the cycling program provides a final result. The operation of the Smart Cycler® instrument is based on the proprietary microprocessor-controlled I-CORE® (Intelligent Cooling/Heating Optical Reaction) module. Each Smart Cycler® processing block contains 16 independently controlled, programmable I-Core® modules, each with one reaction site. Thermally optimized proprietary reaction tubes combined with the design of the I-CORE® modules allow very rapid temperature cycling and rapid amplification. Up to 6 Smart Cycler® processing blocks can be daisy-chained together, allowing simultaneous analysis of 96 discrete samples.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
vaginal/rectal specimens
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A multi-center study was conducted on 803 vaginal/rectal swab specimens collected from intrapatum maternity patients. The samples were evaluated with the IDI-Strep B™ assay and broth culture.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A multi-center study was conducted on 803 vaginal/rectal swab specimens collected from intrapatum maternity patients. The samples were evaluated with the IDI-Strep B™ assay and broth culture.
Results:
Overall Study
Positive IDI-Strep B™ (140), Negative IDI-Strep B™ (9), Total Culture Positive (149)
Positive IDI-Strep B™ (27), Negative IDI-Strep B™ (626), Total Culture Negative (653)
Total IDI-Strep B™ Positive (167), Total IDI-Strep B™ Negative (635), Total (802)
- A Fourteen (14) specimens were initially culture negative but upon investigation were found to be culture positive; 1 of the 14 (specimen #898) had initially tested unresolved but upon re-testing gave a positive result; 3 specimens that were initially IDI-Strep B™ positive were retested because of invalid controls (positive and negative) and tested positive
- B One (1) specimen that was initially positive with IDI-Strep B™ was retested because of an invalid control and re-tested positive
- C Twelve (12) specimens that were initially negative with IDI-Strep B™ were refested because of an invalid control and all tested negative; 8 specimens that initially gave an unresolved result gave a negative result upon retesting
One specimen that gave an initially unresolved result remained unresolved upon retesting and was not included in the table above. Overall, 192 runs were conducted during the study. There were 5 invalid runs due to invalid controls. A total of 16 specimens were included in those runs.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Overall study:
Clinical Sensitivity: 94,% (89.0%- 97.2%)
Clinical Specificity: 95.9% (94.0% - 97.3%)
% unresolved specimens: 1.2%
% invalid runs: 2.6%
For the population tested in this study, negative predictive value of 98.6% (Cl. 97.3% - 99.3%) and a positive predictive value of 83.8% (Cl. 77.4% - 89.1%).
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.3740
Streptococcus spp. serological reagents.(a)
Identification. Streptococcus spp. serological reagents are devices that consist of antigens and antisera (excluding streptococcal exoenzyme reagents made from enzymes secreted by streptococci) used in serological tests to identifyStreptococcus spp. from cultured isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by bacteria belonging to the genusStreptococcus and provides epidemiological information on these diseases. Pathogenic streptococci are associated with infections, such as sore throat, impetigo (an infection characterized by small pustules on the skin), urinary tract infections, rheumatic fever, and kidney disease.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
0
510(k) Summary
NOV 1 8 2002
July 26, 2002
Infectio Diagnostic Inc. IDI-Strep B™ assay
| Submitted by: | Infectio Diagnostic Inc.
2050, boul. René-Lévesque O, 4ᵉ étage
Sainte-Foy, Québec
Canada
G1V 2K8 | | |
|-----------------|--------------------------------------------------------------------------------------------------------------|--|--|
| Contact: | Christian Choquet, PhD. | | |
| Name of Device: | | | |
| Trade Name: | IDL-Strep B™ Assay | | |
| Trade Name: | IDI-Strep B™ Assay |
|---|---|
| Common Name: | Group B streptococcus detection assay |
| Classification Name: | Streptococcus spp. Serological reagents |
Predicate Device:
Thermo BioStar™ STREP B OIA®
Device Description:
Intended Use: IDI-Strep B™ assay is a qualitative in vitro diagnostic test for the rapid detection of Group B streptococcus (GBS) in vaginal/rectal specimens from intrapartum maternity patients. The test performed on the Smart Cycler® automated analyzer utilizes polymerase chain reaction (PCR) for the amplification of GBS DNA recovered from clinical samples and fluorogenic target-specific hybridization for the detection of the amplified GBS DNA.
IDI-Strep B™ assay can be used as the sole diagnostic information at the time of delivery for establishing GBS colonisation status of intrapartum maternity patients.
Test Description: GBS collected from a vaginal/rectal swab is resuspended in sample preparation buffer. A sample is added to the lysing tube containing glass beads. The proprietary procedure is based on a combination of chemical and physical (glass beads) action and takes less than 10 minutes. A sample of the lysate solution is then added to the tube containing the PCR master mix which has the GBS-specific primers used to amplify the GBS ofb gene, if present, and the internal control (IC) template. Finally, 25 µi is transferred to the reaction tube which is placed in the Smart Cycler® assay.
Amplified target DNA is detected with hybridization probes labeled with quenched fluorophores, i.e. molecular beacons. Different fluorophores are used for the GBS amplicon and for the detection of the IC amplicon. Their detection is independent of one another. Amplification of the internal control monitors for inhibitors potentially introduced with the clinical specimen and, in negative specimens, confirms the integrity of assay reagents. The interpretation of the data collected by the Smart Cycler® is made entirely by the diagnostic software of the Smart Cycler® instrument.
The amount of fluorescence at any given cycle, or following cycling, depends on the amount of specific amplicon present at that time. The Smart Cvcler® instrument monitors simultaneously the fluorescence emitted by each beacon, interprets all data and at the end of the cycling program provides a final result. The operation of the Smart Cycler® instrument is based on the proprietary microprocessor-controlled I-CORE® (Intelligent Cooling/Heating Optical Reaction) module. Each
1
Smart Cycler® processing block contains 16 independently controlled, programmable I-Core® modules, each with one reaction site. Thermally optimized proprietary reaction tubes combined with the design of the I-CORE® modules allow very rapid temperature cycling and rapid amplification. Up to 6 Smart Cycler® processing blocks can be daisy-chained together, allowing simultaneous analysis of 96 discrete samples.
Substantial Equivalence:
The Infectio Diagnostic Inc. IDI-Strep B™ assay has been found to be substantially equivalent to the Thermo BioStar™ STREP B OIA® (K991828) and to broth culture. All assays detect GBS; the IDI-Strep B™ assay determines the presence of GBS through PCR amplification and fluorogenic target-specific hybridization detection; BioStar STREP B OIA® assay uses optical immunoassay technology for the detection of GBS antigen; broth culture uses culture characteristics for identification.
A multi-center study was conducted on 803 vaginal/rectal swab specimens collected from intrapatum maternity patients. The samples were evaluated with the IDI-Strep B™ assay and broth culture.
The results of the studies are summarized in the following table.
Summary of Clinical Trial Results
| IDI-Strep B™ | ||||
|---|---|---|---|---|
| Positive | Negative | Total | ||
| Culture technique | Positive | 140A | 9 | 149 |
| Negative | 27B | 626C | 653 | |
| Total | 167 | 635 | 802 |
Overall Study
- A Fourteen (14) specimens were initially culture negative but upon investigation were found to be culture positive; 1 of the 14 (specimen #898) had initially tested unresolved but upon re-testing gave a positive result; 3 specimens that were initially IDI-Strep B™ positive were retested because of invalid controls (positive and negative) and tested positive
- B One (1) specimen that was initially positive with IDI-Strep B™ was retested because of an invalid control and re-tested positive
- C Twelve (12) specimens that were initially negative with IDI-Strep B™ were refested because of an invalid control and all tested negative; 8 specimens that initially gave an unresolved result gave a negative result upon retesting
One specimen that gave an initially unresolved result remained unresolved upon retesting and was not included in the table above. Overall, 192 runs were conducted during the study. There were 5 invalid runs due to invalid controls. A total of 16 specimens were included in those runs.
2
| Investigational site | Clinical sensitivity
(95% CI) A | Clinical specificity
(95% CI) A | % unresolved
specimens | % invalid
runs |
|----------------------|------------------------------------|------------------------------------|---------------------------|-------------------|
| JGH, Montreal | 93% (68%-100%) | 93% (87%-96%) | 3,0% | 3,6% |
| MWH, Pittsburgh | 88% (69%-97%) | 100% (97%-100%) | 0% | 0% |
| ACH, Calgary | 99% (93-100%) | 97% (94%-98%) | 0.2% | 1.8% |
| WCH, Milwaukee | 85% (54%-98%) | 100% (98%-100%) | 2.0% | 4.7% |
| WHT, Houston | 89% (67%-99%) | 93% (82%-98%) | 4.0% | 4.2% |
| Overall study | 94,%
(89.0%- 97.2%) | 95.9%
(94.0% - 97.3%) | 1.2% | 2.6% |
Performances obtained for each investigational site and for the overall study
^ Binomial 95% confidence intervals
The overall prevalence of the study population was 18.6 %, with the highest prevalence being observed in Pittsburgh (28.7%) and the lowest one in Montreal (9.1%). For the population tested in this study, this results in a negative predictive value of 98.6% (Cl. 97.3% - 99.3%) and a positive predictive value of 83.8% (Cl. 77.4% - 89.1%).
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three curved lines representing its wings. The eagle's head is facing to the left, and its body is formed by a negative space silhouette of a human profile. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 098 Gaither Road Rockville MD 20850
Infectio Diagnostic (I.D.I.) Inc. c/o Ms. Judi Smith Principal Sienna Partners, L.L.C. P.O. Box 103 Baldwin, MD 21013
Re: K022504
Trade/Device Name: IDI- Strep BTM Assay Regulation Number: 21 CFR 866.3740 Regulation Name: Streptococcus Spp. Serological Reagents Regulatory Class: Class I Product Code: NJR Dated: October 23, 2002 Received: October 24, 2002
Dear Ms. Smith:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820).
4
Page 2 –
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours.
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
INDICATIONS FOR USE STATEMENT
510(k) Number (if known): K02250 Y
Device Name: _______IDI Strep B
Indications For Use:
Intended Use: IDI-Strep B™ assay is a qualitative in vitro diagnostic test for the rapid detection of Group B streptococcus (GBS) DNA in vaginal/rectal specimens from prepartum or intrapartum women. The test performed on the Smart Cycler® automated analyzer utilizes polymerase chain reaction (PCR) for the amplification of a cfb gene sequence of GBS recovered from clinical samples and fluorogenic target-specific hybridization for the detection of the amplified DNA.
IDI-Strep B™ assay can be used to establish GBS colonisation status of prepartum and intrapartum women.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Luddi L. Poole
on Sion-Off Division of Clinical Laboratory Devices
510(k) Number K022504
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use (Optional Format 1-2-96)